Piramal Pharma Solutions
Piramal Pharma Solutions is a global B2B CDMO providing end-to-end pharmaceutical development and manufacturing services, from drug discovery to commercial supply, serving pharmaceutical innovators and biotech companies across 15+ facilities in North America, Europe, and Asia.
- Company typePrivate
- Founded1990
- HeadquartersRiverview, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Piramal Pharma Solutions does
Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the entire drug lifecycle, from discovery through commercial supply. The company serves pharmaceutical innovators and biotech companies requiring integrated development and manufacturing solutions. Core service offerings include drug discovery (synthetic chemistry, in-vitro biology, DMPK, route scouting), drug substance/API manufacturing (including specialized high-potency APIs, peptides, and hormonal APIs), drug product formulation and manufacturing (oral solids, sterile injectables, liquids, creams, ointments), and Antibody Drug Conjugates supported by the ADCelerate™ integrated platform. Additional capabilities include vaccines and biologics through associate company Yapan Bio, and nutrition solutions. Notable technical assets include proprietary payload-linker manufacturing, isolator-based sterile fill/finish technology, and digital quality tools (eLab, exForms, iAssist, RESOLVE).
The company operates approximately 15 global facilities across North America (US, Canada), Europe (UK), and Asia (India, China), with a commercial presence in over 100 countries. Manufacturing scale includes 245+ reactors, over 750 kL volumetric capacity, 4.5 billion OSD units/year, and 1,500+ ADC batches delivered to date. The CDMO segment accounts for 55% of parent company Piramal Pharma Limited's FY2026 revenue of 8,869 Crore Rupees, with 66% of sales generated from regulated markets. The company employs 7,285+ people globally (zero workplace fatalities for five consecutive years) and serves 500+ international clients.
Business model is contract-based B2B CDMO services with quote-based pricing not publicly disclosed. Go-to-market is direct enterprise sales with Integrated Program Managers assigned as single points of contact for cross-geography project coordination. The company has passed 365+ regulatory inspections including USFDA, EU GMP, MHRA, PMDA, and ANVISA with zero OAI observations, and holds a Net Promoter Score of 55 for FY2025. Piramal Pharma Solutions is a wholly-owned subsidiary of Piramal Pharma Limited (publicly listed in India), which is part of the Piramal Group conglomerate.
Piramal Pharma Solutions firmographics
Firmographics- Name
- Piramal Pharma Solutions
- Legal name
- Piramal Enterprises Limited
- Website
- https://piramalpharmasolutions.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Piramal Pharma Solutions is a global B2B CDMO providing end-to-end pharmaceutical development and manufacturing services, from drug discovery to commercial supply, serving pharmaceutical innovators and biotech companies across 15+ facilities in North America, Europe, and Asia.
- Ownership category
- akta.pro rank
Piramal Pharma Solutions industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing Organization (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Piramal Pharma Solutions is headquartered
LocationHeadquarters
- HQ city
- Riverview
- HQ country
- United States
- HQ region
- North America
Offices13 records
Markets served
Piramal Pharma Solutions business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing (CDMO) Services: Piramal Pharma Solutions generates revenue through contract development and manufacturing services for pharmaceutical companies. The CDMO segment (Piramal Pharma Solutions division) accounts for 55% of parent company Piramal Pharma Limited's revenue. Services include drug substance manufacturing, drug product manufacturing, and specialized offerings.
- API Manufacturing and Sales: Manufacturing and supply of Active Pharmaceutical Ingredients (APIs) including generic APIs, high potency APIs (HPAPIs), peptides, and hormonal APIs across global facilities.
- Drug Product Manufacturing: Clinical and commercial manufacturing of oral solids, sterile injectables, liquids, creams, and ointments with packaging services.
- Specialized Services: ADC development and manufacturing, vaccine and biologics manufacturing through associate company Yapan Bio, and nutrition solutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Piramal Pharma Solutions product offering
Product offeringCore offering
Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the drug lifecycle, from discovery through commercialization. Core offerings include drug discovery services (synthetic chemistry, in-vitro biology, DMPK), drug substance/API development and manufacturing (including high-potency, peptides, hormonal, and controlled substances), drug product formulation and manufacturing (oral solids, liquids, creams, ointments, sterile injectables), and specialized offerings in antibody drug conjugates (via the ADCelerate platform), vaccines and biologics, and nutrition solutions.
Product overview
Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical services spanning the entire drug lifecycle. The company operates as a unified platform combining Drug Discovery Services (synthetic chemistry, in-vitro biology, DMPK, route scouting), Drug Substance/API Manufacturing (including specialized HPAPI, peptides, and hormonal APIs), Drug Product services (formulation development, oral solids, sterile injectables), and Antibody Drug Conjugates (supported by the ADCelerate™ platform). Additional specialized offerings include Vaccines and Biologics through associate company Yapan Bio, and Nutrition Solutions. The portfolio also includes digital quality tools (eLab, exForms, iAssist, RESOLVE) and the Science Collective expert team. Services are delivered through 15 global facilities across North America, Europe, and Asia.
Differentiator
Problem solved
Functional benefit
Brands
- ADCelerate: Integrated ADC solution that accelerates timelines for developing initial clinical supply of both drug substance and drug product
- Nicomix
- MaxReti
- RESOLVE
- eLab
- exForms
- iAssist
Products and services
- Drug Discovery Services Comprehensive drug discovery services including synthetic chemistry, in-vitro biology, in-vitro ADME, route scouting, analytical support, and non-GMP kilo lab services for pharmaceutical, biotech, and academic customers.
- Drug Substance (API Development & Manufacturing) End-to-end active pharmaceutical ingredient (API) development and manufacturing services including route scouting, process and analytical development, pre-GMP scale-up, and pre-clinical, clinical, and commercial supply for pharmaceutical innovators.
- Generic APIs Manufacturing and supply of generic active pharmaceutical ingredients for commercial pharmaceutical products across global facilities.
- Special APIs (HPAPI, Peptides, Hormonal, Controlled Substances) Specialized API manufacturing capabilities for high potency APIs (HPAPI), peptides, hormonal APIs, and controlled substances with advanced containment facilities such as high-potency manufacturing with OEL down to 0.01 µg/m³.
- Drug Product (Formulation Development & Manufacturing) Formulation development and commercial manufacturing of oral solids, liquids, creams, ointments, sterile injectables, controlled substances, potent OSDs, and hormonal formulations for clinical and commercial supply.
- Sterile Injectables Sterile injectable manufacturing including formulation development, fill-finish, lyophilization, and aseptic processing with Grade A isolator-based technology for potent compounds, cytotoxics, hormones, and steroids.
- Antibody Drug Conjugates (ADCs) End-to-end antibody-drug conjugate development and manufacturing including payload-linker development, conjugation, and fill-finish services across Grangemouth (UK), Riverview (USA), and Lexington (USA) sites. First FDA-approved ADC CDMO with 20+ years of experience and 1,500+ ADC batches manufactured.
- ADCelerate Proprietary integrated ADC solution platform that accelerates timelines for developing initial clinical supply of both drug substance and drug product, covering preclinical to commercial-scale manufacturing via the ADCelerate program.
- Peptides End-to-end peptide API development and manufacturing services including both solution phase and solid phase synthesis capabilities, regulatory filings, and characterization for commercial supply.
- Vaccines and Biologics Development and manufacturing services for vaccines, gene therapy, monoclonal antibodies, and other complex biologics up to 1,000L scale, delivered through associate company Yapan Bio at the Hyderabad facility with BSL-2+ containment.
- Nutrition Solutions Comprehensive nutrition solutions including human nutrition premixes (vitamin mineral, fortification, customized), animal nutrition products (Nicomix vitamin premix, liquid feed supplements), skincare ingredients (MaxReti retinol products), and food fortification programs.
Quantifiable outcome
- Zero OAI observations across all USFDA inspections
- +4 more outcomes
Companies that use Piramal Pharma Solutions
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Piramal Pharma Solutions technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Piramal Pharma Solutions partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- Botanix SB Inc.coreManufacturing and supply agreement for Sofdra (sofpironium bromide), the first FDA-approved new chemical entity for treating primary axillary hyperhidrosis. PPS will perform development and validation at Riverview, Michigan with potential dual-source production at Aurora, Canada facility to provide supply chain redundancy and cost efficiencies. Partnership expected to significantly reduce Botanix's cost of goods sold while ensuring consistent patient access.
- Ajinomoto Bio-Pharma ServicescoreStrategic collaboration to support ADC development and manufacturing. Piramal will refer ADC manufacturing customers to Ajinomoto's AJICAP technology platform while Ajinomoto will refer customers to Piramal for CDMO services. Companies entered Material Transfer Agreement enabling technology transfer for Piramal to manufacture AJICAP-based products. Combines Ajinomoto's site-specific conjugation technology with Piramal's clinical and commercial ADC GMP manufacturing expertise.
- IntoCellsupportingFormalized partnership through Memorandum of Understanding to expand bioconjugate capabilities and ADC development services. Agreement involves exploring licensing of IntoCell's drug-linker technologies and offering contract research and manufacturing services.
- Yapan BiocoreAssociate company providing biologics and vaccine development and manufacturing services. Yapan Bio specializes in process development, scale-up, and GMP-compliant manufacturing of vaccines, gene therapy, monoclonal antibodies, and other complex biologics. Piramal leverages this partnership to offer integrated large molecule services.
Scale indicators14 records
Recent moves10 records
Expansion highlights4 records
Piramal Pharma Solutions competitors and assessment
Company assessmentDirect peers
- Catalent: One of the largest pure-play CDMOs globally, offering integrated drug substance, drug product, biologics, and ADC capabilities. Direct competitor to Piramal across formulation, fill-finish, and biologics CDMO services.
- Lonza: Global CDMO leader in biologics, small molecules, and cell & gene therapies. Comparable to Piramal in small-molecule API manufacturing and overlapping in sterile fill-finish and biologics CDMO.
- Samsung Biologics: Major biologics CDMO with large-scale mammalian cell culture capacity. Overlaps with Piramal/Yapan Bio in biologics and vaccine contract manufacturing.
- WuXi STA: Subsidiary of WuXi AppTec providing integrated API and drug product CDMO services. Direct overlap with Piramal's API manufacturing and formulation development offerings.
- Recipharm: European-headquartered CDMO with strong sterile injectables and oral solids capabilities. Comparable to Piramal in drug product contract manufacturing and HPAPI handling.
- Curia: Global CDMO offering integrated API and drug product services including HPAPIs and complex chemistry. Direct mid-tier CDMO competitor with overlapping capabilities to Piramal.
Broad incumbents
- Thermo Fisher Scientific (CDMO / Patheon): Operates a large CDMO business via Patheon. Broader portfolio than Piramal but directly competes across API, drug product, and sterile injectable contract manufacturing.
- Boehringer Ingelheim BioXcellence: Biologics CDMO division of Boehringer Ingelheim, providing process development and commercial manufacturing for biopharmaceuticals. Comparable to Piramal/Yapan Bio's biologics offering.
- Eurofins CDMO: Eurofins' pharmaceutical CDMO operations offer API development and manufacturing services with global reach, comparable to Piramal's small-molecule API business.
Regional players
- Syngene International: India-based CRO/CDMO providing discovery, development, and manufacturing services. Strong geographic and capability overlap with Piramal's India-based operations and integrated CDMO model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Piramal Pharma Solutions social profiles
Digital presencePiramal Pharma Solutions compliance and trust
Trust signalCompliance18 records
Piramal Pharma Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Piramal Pharma Solutions leadership team
Management profileNumber of profiles
Profiles9 records
Piramal Pharma Solutions subsidiaries and ownership
Company hierarchySubsidiaries1 record
Piramal Pharma Solutions funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Piramal Pharma Solutions M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Piramal Pharma Solutions
What does Piramal Pharma Solutions do?
Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the drug lifecycle, from discovery through commercialization. Core offerings include drug discovery services (synthetic chemistry, in-vitro biology, DMPK), drug substance/API development and manufacturing (including high-potency, peptides, hormonal, and controlled substances), drug product formulation and manufacturing (oral solids, liquids, creams, ointments, sterile injectables), and specialized offerings in antibody drug conjugates (via the ADCelerate platform), vaccines and biologics, and nutrition solutions.
Is Piramal Pharma Solutions a public or private company?
Piramal Pharma Solutions is a private company. It is classified as corporate owned and is currently operating.
When was Piramal Pharma Solutions founded?
Piramal Pharma Solutions was founded in 1990. It employs 1,001 to 5,000 people.
Where is Piramal Pharma Solutions based?
Piramal Pharma Solutions is headquartered in Riverview, United States, in the North America region.
How does Piramal Pharma Solutions make money?
Four revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are API Manufacturing and Sales, drug Product Manufacturing and specialized Services.
Who are Piramal Pharma Solutions's main competitors?
Direct peers on record are Catalent, Lonza, Samsung Biologics, WuXi STA, Recipharm and Curia. Broad incumbents are Thermo Fisher Scientific (CDMO / Patheon), Boehringer Ingelheim BioXcellence and Eurofins CDMO. Syngene International is listed as a regional player.
Does Piramal Pharma Solutions have an API?
No public API is recorded for Piramal Pharma Solutions.
What industry is Piramal Pharma Solutions in?
Piramal Pharma Solutions's product category is Pharmaceutical Contract Development and Manufacturing Organization (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.